{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:00:48Z","timestamp":1790402448326,"version":"4.1.0"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T00:00:00Z","timestamp":1623196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bisoprolol and nebivolol are highly selective \u03b2<jats:sub>1<\/jats:sub>-adrenoceptor antagonists, with clinical indications in many countries within the management of heart failure with reduced left ventricular ejection fraction (HFrEF), ischaemic heart disease (IHD), and hypertension. Nebivolol has additional vasodilator actions, related to enhanced release of NO in the vascular wall. In principle, this additional mechanism compared with bisoprolol might lead to more potent vasodilatation, which in turn might influence the effectiveness of nebivolol in the management of HFrEF, IHD and hypertension. In this article, we review the therapeutic properties of bisoprolol and nebivolol, as representatives of \u201csecond generation\u201d and \u201cthird generation\u201d \u03b2-blockers, respectively. Although head-to-head trials are largely lacking, there is no clear indication from published studies of an additional effect of nebivolol on clinical outcomes in patients with HFrEF or the magnitude of reductions of BP in patients with hypertension.<\/jats:p>","DOI":"10.1007\/s10557-021-07205-y","type":"journal-article","created":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T07:14:27Z","timestamp":1623222867000},"page":"959-971","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Therapeutic Properties of Highly Selective \u03b2-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease"],"prefix":"10.1007","volume":"36","author":[{"given":"Waleed","family":"AlHabeeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanaa","family":"Mrabeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Adel Ibrahim","family":"Abdelsalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,9]]},"reference":[{"key":"7205_CR1","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1161\/01.CIR.0000016050.79810.18","volume":"105","author":"P Andreka","year":"2002","unstructured":"Andreka P, Aiyar N, Olson LC, et al. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation. 2002;105:2429\u201334.","journal-title":"Circulation"},{"issue":"5 Suppl","key":"7205_CR2","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.cjca.2013.12.001","volume":"30","author":"L Poirier","year":"2014","unstructured":"Poirier L, Tobe SW. Contemporary use of \u03b2-blockers: clinical relevance of subclassification. Can J Cardiol. 2014;30(5 Suppl):S9\u201315.","journal-title":"Can J Cardiol"},{"key":"7205_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1002\/j.1875-9114.1983.tb03252.x","volume":"3","author":"EP MacCarthy","year":"1983","unstructured":"MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy. 1983;3:193\u2013219.","journal-title":"Pharmacotherapy"},{"key":"7205_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/CRD.0000000000000159","volume":"25","author":"JJ Nawarskas","year":"2017","unstructured":"Nawarskas JJ, Cheng-Lai A, Frishman WH. Celiprolol: a unique selective adrenoceptor modulator. Cardiol Rev. 2017;25:247\u201353.","journal-title":"Cardiol Rev"},{"key":"7205_CR5","unstructured":"National Institute for Health and Care Excellence. Beta-adrenoceptor blocking drugs. Overview. Available at https:\/\/bnf.nice.org.uk\/treatment-summary\/beta-adrenoceptor-blocking-drugs.html (accessed April 2021)."},{"key":"7205_CR6","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","volume":"318","author":"N Freemantle","year":"1999","unstructured":"Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999;318:1730\u20137.","journal-title":"BMJ"},{"key":"7205_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ijcard.2007.01.069","volume":"120","author":"JM Cruickshank","year":"2007","unstructured":"Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol. 2007;120:10\u201327.","journal-title":"Int J Cardiol"},{"key":"7205_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1440-1681.1986.tb00316.x","volume":"13","author":"JF Marwood","year":"1986","unstructured":"Marwood JF, Stokes GS. Studies on the vasodilator actions of bucindolol in the rat. Clin Exp Pharmacol Physiol. 1986;13:59\u201368.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"7205_CR9","unstructured":"Farzam K. Beta blockers. Stat Pearls (internet). Available at https:\/\/www.statpearls.com\/kb\/viewarticle\/18241 (accessed April 2021)."},{"key":"7205_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1177\/1753944709104496","volume":"3","author":"A Maffei","year":"2009","unstructured":"Maffei A, Lembo G. Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis. 2009;3:317\u201327.","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"Suppl 3","key":"7205_CR11","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/00005344-200112003-00003","volume":"38","author":"JM Ritter","year":"2001","unstructured":"Ritter JM. Nebivolol: endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol. 2001;38(Suppl 3):S13\u20136.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7205_CR12","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40265-015-0435-5","volume":"75","author":"J Fongemie","year":"2015","unstructured":"Fongemie J, Felix-Getzik E. A review of nebivolol pharmacology and clinical evidence. Drugs. 2015;75:1349\u201371.","journal-title":"Drugs"},{"key":"7205_CR13","unstructured":"Stoschitzky K. Individual beta-blockers for individual patients. e-journal of the ESC Council for Cardiology Practice. 2008;6:15 Jan 2008. Available at https:\/\/www.escardio.org\/Journals\/E-Journal-of-Cardiology-Practice\/Volume-6\/Individual-beta-blockers-for-individual-patients-Title-Individual-beta-blocke (accessed April 2021)."},{"key":"7205_CR14","doi-asserted-by":"crossref","unstructured":"Koracevic G, Micic S, Stojanovic M, et al. Compelling indications should be listed for individual beta-blockers (due to diversity), not for the whole class [published online ahead of print, 2020 May 18]. Curr Vasc Pharmacol. 2021;19:343\u201346.","DOI":"10.2174\/1570161118666200518113833"},{"key":"7205_CR15","doi-asserted-by":"publisher","first-page":"104785","DOI":"10.1016\/j.phrs.2020.104785","volume":"156","author":"G Sinagra","year":"2020","unstructured":"Sinagra G, Corr\u00e0 U, Contini M, et al. Choosing among \u03b2-blockers in heart failure patients according to \u03b2-receptors\u2019 location and functions in the cardiopulmonary system. Pharmacol Res. 2020;156:104785.","journal-title":"Pharmacol Res"},{"key":"7205_CR16","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1136\/bmj.1.6024.1498","volume":"1","author":"AJ Marshall","year":"1976","unstructured":"Marshall AJ, Roberts CJ, Barritt DW. Raynaud\u2019s phenomenon as side effect of beta-blockers in hypertension. Br Med J. 1976;1:1498\u20139.","journal-title":"Br Med J"},{"key":"7205_CR17","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1185\/03007990903533681","volume":"26","author":"VA Fonseca","year":"2010","unstructured":"Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin. 2010;26:615\u201329.","journal-title":"Curr Med Res Opin"},{"key":"7205_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/bcp.12543","volume":"79","author":"JA Hirst","year":"2015","unstructured":"Hirst JA, Farmer AJ, Feakins BG, Aronson JK, Stevens RJ. Quantifying the effects of diuretics and \u03b2-adrenoceptor blockers on glycaemic control in diabetes mellitus \u2014 a systematic review and meta-analysis. Br J Clin Pharmacol. 2015;79:733\u201343.","journal-title":"Br J Clin Pharmacol"},{"key":"7205_CR19","first-page":"357","volume":"23","author":"LL Van de Ven","year":"1994","unstructured":"Van de Ven LL, Van Leeuwen JT, Smit AJ. The influence of chronic treatment with betablockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial. Vasa. 1994;23:357\u201362.","journal-title":"Vasa"},{"key":"7205_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1753944712459593","volume":"6","author":"FW Germino","year":"2012","unstructured":"Germino FW, Lin Y, Pejovi\u0107 V, Bowen L. Efficacy and tolerability of nebivolol: does age matter? A retrospective analysis of three randomized, placebo-controlled trials in stage I-II hypertension. Ther Adv Cardiovasc Dis. 2012;6:185\u201399.","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"7205_CR21","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1016\/j.ijcard.2013.05.068","volume":"168","author":"AJ Barron","year":"2013","unstructured":"Barron AJ, Zaman N, Cole GD, Wensel R, Okonko DO, Francis DP. Systematic review of genuine versus spurious side-effects of beta-blockers in heart failure using placebo control: recommendations for patient information. Int J Cardiol. 2013;168:3572\u20139.","journal-title":"Int J Cardiol"},{"key":"7205_CR22","doi-asserted-by":"publisher","first-page":"f6745","DOI":"10.1136\/bmj.f6745","volume":"347","author":"L Shen","year":"2013","unstructured":"Shen L, Shah BR, Reyes EM, et al. Role of diuretics, \u03b2 blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ. 2013;347:f6745.","journal-title":"BMJ"},{"key":"7205_CR23","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/HJH.0b013e3282f283c9","volume":"26","author":"Z Dhakam","year":"2008","unstructured":"Dhakam Z, Yasmin, McEniery CM, Burton T, Brown MJ, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens. 2008;26:351\u20136.","journal-title":"J Hypertens"},{"key":"7205_CR24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1475-2840-11-14","volume":"11","author":"B Wai","year":"2012","unstructured":"Wai B, Kearney LG, Hare DL, Ord M, Burrell LM, Srivastava PM. Beta blocker use in subjects with type 2 diabetes mellitus and systolic heart failure does not worsen glycaemic control. Cardiovasc Diabetol. 2012;11:14.","journal-title":"Cardiovasc Diabetol"},{"issue":"Suppl 11","key":"7205_CR25","first-page":"S96","volume":"8","author":"HU Janka","year":"1986","unstructured":"Janka HU, Ziegler AG, Disselhoff G, Mehnert H. Influence of bisoprolol on blood glucose, glucosuria, and haemoglobin A1 in noninsulin-dependent diabetics. J Cardiovasc Pharmacol. 1986;8(Suppl 11):S96\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7205_CR26","first-page":"749","volume":"14","author":"LM Van Bortel","year":"2010","unstructured":"Van Bortel LM. Efficacy, tolerability and safety of nebivolol in patients with hypertension and diabetes: a post-marketing surveillance study. Eur Rev Med Pharmacol Sci. 2010;14:749\u201358.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"7205_CR27","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1161\/HYPERTENSIONAHA.111.189589","volume":"59","author":"K Ayers","year":"2012","unstructured":"Ayers K, Byrne LM, DeMatteo A, Brown NJ. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension. 2012;59:893\u20138.","journal-title":"Hypertension"},{"key":"7205_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/jch.12071","volume":"15","author":"P Deedwania","year":"2013","unstructured":"Deedwania P, Shea J, Chen W, Brener L. Effects of add-on nebivolol on blood pressure and glucose parameters in hypertensive patients with prediabetes. J Clin Hypertens (Greenwich). 2013;15:270\u20138.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"7205_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11906-017-0716-3","volume":"19","author":"M Marketou","year":"2017","unstructured":"Marketou M, Gupta Y, Jain S, Vardas P. Differential metabolic effects of beta-blockers: an updated systematic review of nebivolol. Curr Hypertens Rep. 2017;19:22.","journal-title":"Curr Hypertens Rep"},{"key":"7205_CR30","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1183\/13993003.01847-2015","volume":"48","author":"B Lipworth","year":"2016","unstructured":"Lipworth B, Wedzicha J, Devereux G, Vestbo J, Dransfield MT. Beta-blockers in COPD: time for reappraisal. Eur Respir J. 2016;48:880\u20138.","journal-title":"Eur Respir J"},{"key":"7205_CR31","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12916-017-0781-0","volume":"15","author":"DR Morales","year":"2017","unstructured":"Morales DR, Lipworth BJ, Donnan PT, Jackson C, Guthrie B. Respiratory effect of beta-blockers in people with asthma and cardiovascular disease: population-based nested case control study. BMC Med. 2017;15:18.","journal-title":"BMC Med"},{"key":"7205_CR32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/resp.13955","volume":"26","author":"MR Bennett","year":"2021","unstructured":"Bennett MR, Chang CL, Tuffery C, Hopping S, Hancox RJ. The impact of regular bisoprolol on the response to salbutamol in asthma: a double-blind randomized placebo-controlled crossover trial. Respirology. 2021;26:225\u201332.","journal-title":"Respirology"},{"key":"7205_CR33","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.2147\/COPD.S144333","volume":"12","author":"KP Lim","year":"2017","unstructured":"Lim KP, Loughrey S, Musk M, Lavender M, Wrobel JP. Beta-blocker under-use in COPD patients. Int J Chron Obstruct Pulmon Dis. 2017;12:3041\u20136.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"7205_CR34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1161\/HYPERTENSIONAHA.110.169169","volume":"58","author":"C Espinola-Klein","year":"2011","unstructured":"Espinola-Klein C, Weisser G, Jagodzinski A, et al. \u03b2-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension. 2011;58:148\u201354.","journal-title":"Hypertension"},{"key":"7205_CR35","first-page":"48","volume":"53","author":"II Mustafaev","year":"2013","unstructured":"Mustafaev II, Nurmamedova GS. Effect of monotherapy with nebivolol, bisoprolol, carvedilol on the state of vegetative nervous system and sexual function in men with arterial hypertension. Kardiologiia. 2013;53:48\u201354.","journal-title":"Kardiologiia"},{"key":"7205_CR36","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/00926239208412857","volume":"18","author":"CP Broekman","year":"1992","unstructured":"Broekman CP, Haensel SM, Van de Ven LL, Slob AK. Bisoprolol and hypertension: effects on sexual functioning in men. J Sex Marital Ther. 1992;18:325\u201331.","journal-title":"J Sex Marital Ther"},{"key":"7205_CR37","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1517\/13543784.2011.625011","volume":"20","author":"N Riva","year":"2011","unstructured":"Riva N, Lip GY. Nebivolol for the treatment of heart failure. Expert Opin Investig Drugs. 2011;20:1733\u201346.","journal-title":"Expert Opin Investig Drugs"},{"key":"7205_CR38","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1440-1681.2007.04551.x","volume":"34","author":"K Brixius","year":"2007","unstructured":"Brixius K, Middeke M, Lichtenthal A, Jahn E, Schwinger RH. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol. 2007;34:327\u201331.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"7205_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.5761\/atcs.oa.16-00242","volume":"23","author":"\u00d6 G\u00fcr","year":"2017","unstructured":"G\u00fcr \u00d6, Gurkan S, Yumun G, Turker P. The comparison of the effects of nebivolol and metoprolol on erectile dysfunction in the cases with coronary artery bypass surgery. Ann Thorac Cardiovasc Surg. 2017;23:91\u20135.","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"7205_CR40","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2165\/00044011-200525060-00006","volume":"25","author":"B Boydak","year":"2005","unstructured":"Boydak B, Nalbantgil S, Fici F, et al. A randomised comparison of the effects of nebivolol and atenolol with and without chlorthalidone on the sexual function of hypertensive men. Clin Drug Investig. 2005;25:409\u201316.","journal-title":"Clin Drug Investig"},{"key":"7205_CR41","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1755-5922.2009.00123.x","volume":"28","author":"A Cordero","year":"2010","unstructured":"Cordero A, Bertomeu-Mart\u00ednez V, Maz\u00f3n P, et al. Erectile dysfunction in high-risk hypertensive patients treated with beta-blockade agents. Cardiovasc Ther. 2010;28:15\u201322.","journal-title":"Cardiovasc Ther"},{"key":"7205_CR42","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1745-7262.2006.00076.x","volume":"8","author":"M Doumas","year":"2006","unstructured":"Doumas M, Tsakiris A, Douma S, et al. Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. Asian J Androl. 2006;8:177\u201382.","journal-title":"Asian J Androl"},{"key":"7205_CR43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1756287216685027","volume":"9","author":"RP Sharp","year":"2017","unstructured":"Sharp RP, Gales BJ. Nebivolol versus other beta blockers in patients with hypertension and erectile dysfunction. Ther Adv Urol. 2017;9:59\u201363.","journal-title":"Ther Adv Urol"},{"key":"7205_CR44","doi-asserted-by":"publisher","first-page":"e13062","DOI":"10.1111\/and.13062","volume":"50","author":"K Ayd\u0131n","year":"2018","unstructured":"Ayd\u0131n K, G\u00f6k\u00e7en K, Y\u0131ld\u0131r\u0131m \u015e, Bagcivan \u0130, Parlak M, G\u00f6k\u00e7e G. In vitro evaluation of nebivolol effects on nonadrenergic noncholinergic responses in rabbit corpus cavernosum. Andrologia. 2018;50:e13062.","journal-title":"Andrologia"},{"key":"7205_CR45","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1111\/jsm.12477","volume":"11","author":"JI Mart\u00ednez-Salamanca","year":"2014","unstructured":"Mart\u00ednez-Salamanca JI, La Fuente JM, et al. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO\/cGMP pathway. J Sex Med. 2014;11:1182\u201392.","journal-title":"J Sex Med"},{"key":"7205_CR46","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/sj.bjp.0704188","volume":"133","author":"K Brixius","year":"2001","unstructured":"Brixius K, Bundkirchen A, B\u00f6lck B, Mehlhorn U, Schwinger RH. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol. 2001;133:1330\u20138.","journal-title":"Br J Pharmacol"},{"key":"7205_CR47","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0014-2999(02)02875-3","volume":"460","author":"A Bundkirchen","year":"2003","unstructured":"Bundkirchen A, Brixius K, B\u00f6lck B, Nguyen Q, Schwinger RH. Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies. Eur J Pharmacol. 2003;460:19\u201326.","journal-title":"Eur J Pharmacol"},{"key":"7205_CR48","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1046\/j.1365-2710.2003.00477.x","volume":"28","author":"SL Nuttall","year":"2003","unstructured":"Nuttall SL, Routledge HC, Kendall MJ. A comparison of the beta1-selectivity of three beta1-selective beta-blockers. J Clin Pharm Ther. 2003;28:179\u201386.","journal-title":"J Clin Pharm Ther"},{"key":"7205_CR49","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1038\/sj.bjp.0703992","volume":"132","author":"C Maack","year":"2001","unstructured":"Maack C, Tyroller S, Schnabel P, et al. Characterization of beta(1)-selectivity, adrenoceptor-G(s)-protein interaction and inverse agonism of nebivolol in human myocardium. Br J Pharmacol. 2001;132:1817\u201326.","journal-title":"Br J Pharmacol"},{"key":"7205_CR50","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/sj.bjp.0706048","volume":"144","author":"JG Baker","year":"2005","unstructured":"Baker JG. The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors. Br J Pharmacol. 2005;144:317\u201322.","journal-title":"Br J Pharmacol"},{"key":"7205_CR51","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/00005344-200010000-00008","volume":"36","author":"P Schnabel","year":"2000","unstructured":"Schnabel P, Maack C, Mies F, Tyroller S, Scheer A, B\u00f6hm M. Binding properties of beta-blockers at recombinant beta1-, beta2-, and beta3-adrenoceptors. J Cardiovasc Pharmacol. 2000;36:466\u201371.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7205_CR52","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/CIRCRESAHA.113.300308","volume":"113","author":"A Lymperopoulos","year":"2013","unstructured":"Lymperopoulos A, Rengo G, Koch WJ. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ Res. 2013;113:739\u201353.","journal-title":"Circ Res"},{"key":"7205_CR53","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/ncpcardio0309","volume":"2","author":"DS Feldman","year":"2005","unstructured":"Feldman DS, Carnes CA, Abraham WT, Bristow MR. Mechanisms of disease: beta-adrenergic receptors\u2013alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med. 2005;2:475\u201383.","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"7205_CR54","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/ajh\/hpw012","volume":"29","author":"G Grassi","year":"2016","unstructured":"Grassi G. Sympathomodulatory effects of antihypertensive drug treatment. Am J Hypertens. 2016;29:665\u201375.","journal-title":"Am J Hypertens"},{"key":"7205_CR55","first-page":"380","volume":"3","author":"J Cruickshank","year":"2014","unstructured":"Cruickshank J. Nebivolol, a third generation beta-blocker. J Signs Symptoms. 2014;3:380\u201391.","journal-title":"J Signs Symptoms"},{"key":"7205_CR56","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.recesp.2019.02.023","volume":"72","author":"E Oliver","year":"2019","unstructured":"Oliver E, Mayor F Jr, D\u2019Ocon P. Beta-blockers: historical perspective and mechanisms of action. Rev Esp Cardiol (Engl Ed). 2019;72:853\u201362.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"7205_CR57","first-page":"380","volume":"3","author":"J Cruickshank","year":"2014","unstructured":"Cruickshank J. Nebivolol, a third generation beta-blocker. J Symptoms Signs. 2014;3:380\u201391.","journal-title":"J Symptoms Signs"},{"key":"7205_CR58","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1023\/A:1026180325278","volume":"17","author":"I Czuriga","year":"2003","unstructured":"Czuriga I, Riecansky I, Bodnar J, et al. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther. 2003;17:257\u201363.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7205_CR59","doi-asserted-by":"publisher","first-page":"492","DOI":"10.4103\/0253-7613.84947","volume":"43","author":"G Khilnani","year":"2011","unstructured":"Khilnani G, Khilnani AK. Inverse agonism and its therapeutic significance. Indian J Pharmacol. 2011;43:492\u2013501.","journal-title":"Indian J Pharmacol"},{"key":"7205_CR60","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s002280050237","volume":"51","author":"G Cheymol","year":"1997","unstructured":"Cheymol G, Woestenborghs R, Snoeck E, et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol. 1997;51:493\u20138.","journal-title":"Eur J Clin Pharmacol"},{"key":"7205_CR61","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/j.1552-4604.1986.tb02959.x","volume":"26","author":"G Leopold","year":"1986","unstructured":"Leopold G, Pabst J, Ungeth\u00fcm W, B\u00fchring KU. Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist. J Clin Pharmacol. 1986;26:616\u201321.","journal-title":"J Clin Pharmacol"},{"key":"7205_CR62","first-page":"188","volume":"34","author":"O Hilas","year":"2009","unstructured":"Hilas O, Ezzo D. Nebivolol (bystolic), a novel Beta blocker for hypertension. P T. 2009;34:188\u201392.","journal-title":"P T"},{"key":"7205_CR63","first-page":"208","volume":"88","author":"C Briciu","year":"2015","unstructured":"Briciu C, Neag M, Muntean D, et al. Phenotypic differences in nebivolol metabolism and bioavailability in healthy volunteers. Clujul Med. 2015;88:208\u201313.","journal-title":"Clujul Med"},{"key":"7205_CR64","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s00228-020-02937-6","volume":"76","author":"S Mom\u010dilovi\u0107","year":"2020","unstructured":"Mom\u010dilovi\u0107 S, Jovanovi\u0107 A, Radojkovi\u0107 D, et al. Population pharmacokinetic analysis of bisoprolol in type 2 diabetic patients with hypertension. Eur J Clin Pharmacol. 2020;76:1539\u201346.","journal-title":"Eur J Clin Pharmacol"},{"key":"7205_CR65","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/FJC.0000000000000644","volume":"73","author":"S Mom\u010dilovi\u0107","year":"2019","unstructured":"Mom\u010dilovi\u0107 S, Milovanovi\u0107 JR, Jankovi\u0107 SM, et al. Population pharmacokinetic analysis of bisoprolol in patients with acute coronary syndrome. J Cardiovasc Pharmacol. 2019;73:136\u201342.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7205_CR66","doi-asserted-by":"publisher","first-page":"e00496","DOI":"10.1002\/prp2.496","volume":"7","author":"FN \u00c5gesen","year":"2019","unstructured":"\u00c5gesen FN, Weeke PE, Tfelt-Hansen P, Tfelt-Hansen J. Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology. Pharmacol Res Perspect. 2019;7:e00496.","journal-title":"Pharmacol Res Perspect"},{"key":"7205_CR67","doi-asserted-by":"publisher","first-page":"e013115","DOI":"10.1161\/JAHA.119.013115","volume":"8","author":"S Singh","year":"2019","unstructured":"Singh S, Warren HR, Hiltunen TP, et al. Genome-wide meta-analysis of blood pressure response to \u03b21-blockers: results from ICAPS (International Consortium of Antihypertensive Pharmacogenomics Studies). J Am Heart Assoc. 2019;8:e013115.","journal-title":"J Am Heart Assoc"},{"key":"7205_CR68","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1097\/HJH.0000000000000714","volume":"33","author":"Y Gong","year":"2015","unstructured":"Gong Y, McDonough CW, Beitelshees AL, et al. PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. J Hypertens. 2015;33:2278\u201385.","journal-title":"J Hypertens"},{"key":"7205_CR69","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1177\/0897190018782794","volume":"33","author":"A Ingram","year":"2020","unstructured":"Ingram A, Valente M. Genetic variation of hepatic enzymes influence on \u03b2-blocker dose in patients with reduced ejection fraction heart failure. J Pharm Pract. 2020;33:96\u20138.","journal-title":"J Pharm Pract"},{"key":"7205_CR70","doi-asserted-by":"publisher","first-page":"e001521","DOI":"10.1161\/JAHA.114.001521","volume":"4","author":"TP Hiltunen","year":"2015","unstructured":"Hiltunen TP, Donner KM, Sarin AP, et al. Pharmacogenomics of hypertension: a genome-wide, placebo-controlled cross-over study, using four classes of antihypertensive drugs. J Am Heart Assoc. 2015;4:e001521.","journal-title":"J Am Heart Assoc"},{"key":"7205_CR71","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/clpt.2012.18","volume":"92","author":"T Rau","year":"2012","unstructured":"Rau T, D\u00fcngen HD, Edelmann F, et al. Impact of the \u03b21-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients. Clin Pharmacol Ther. 2012;92:21\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"7205_CR72","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1016\/j.ijcard.2013.01.277","volume":"168","author":"Apostolo A Contini","year":"2013","unstructured":"Contini Apostolo A, Cattadori G, et al. Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial. Int J Cardiol. 2013;168:2134\u201340.","journal-title":"Int J Cardiol"},{"key":"7205_CR73","first-page":"159","volume":"12","author":"J De Cree","year":"1992","unstructured":"De Cree J, Van Nueten L, Geukens H, Verhaegen H. Comparative cardiac haemodynamics of bisoprolol, celiprolol, carvedilol and nebivolol in normal volunteers. Int J Clin Pharmacol Res. 1992;12:159\u201363.","journal-title":"Int J Clin Pharmacol Res"},{"key":"7205_CR74","doi-asserted-by":"publisher","first-page":"f55","DOI":"10.1136\/bmj.f55","volume":"346","author":"S Chatterjee","year":"2013","unstructured":"Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of \u03b2 blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ. 2013;346:f55.","journal-title":"BMJ"},{"key":"7205_CR75","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1161\/01.CIR.90.4.1765","volume":"90","author":"CIBIS Investigators and Committees","year":"1994","unstructured":"CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation. 1994;90:1765\u201373.","journal-title":"Circulation"},{"key":"7205_CR76","doi-asserted-by":"crossref","unstructured":"CIBIS Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9\u201313.","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"7205_CR77","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.105.582320","volume":"112","author":"R Willenheimer","year":"2005","unstructured":"Willenheimer R, van Veldhuisen D, Silke B, et al. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation. 2005;112:2426\u201335.","journal-title":"Circulation"},{"key":"7205_CR78","doi-asserted-by":"crossref","unstructured":"Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al, for the SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215\u201325","DOI":"10.1093\/eurheartj\/ehi115"},{"key":"7205_CR79","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/S1388-9842(01)00174-X","volume":"3","author":"E Erdmann","year":"2001","unstructured":"Erdmann E, Lechat P, Verkenne P, Wiemann H. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail. 2001;3:469\u201379.","journal-title":"Eur J Heart Fail"},{"key":"7205_CR80","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/eurjhf\/hfr051","volume":"13","author":"C Funck-Brentano","year":"2011","unstructured":"Funck-Brentano C, van Veldhuisen DJ, van de Ven LL, et al. Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS-III trial. Eur J Heart Fail. 2011;13:765\u201372.","journal-title":"Eur J Heart Fail"},{"key":"7205_CR81","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/eurjhf\/hfp104","volume":"11","author":"A Cohen-Solal","year":"2009","unstructured":"Cohen-Solal A, Kotecha D, van Veldhuisen DJ, et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail. 2009;11:872\u201380.","journal-title":"Eur J Heart Fail"},{"key":"7205_CR82","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/ejhf.136","volume":"16","author":"M Montero-Perez-Barquero","year":"2014","unstructured":"Montero-Perez-Barquero M, Flather M, Roughton M, et al. Influence of systolic blood pressure on clinical outcomes in elderly heart failure patients treated with nebivolol: data from the SENIORS trial. Eur J Heart Fail. 2014;16:1009\u201315.","journal-title":"Eur J Heart Fail"},{"key":"7205_CR83","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/0735-1097(96)00122-2","volume":"28","author":"T Von Arnim","year":"1996","unstructured":"Von Arnim T. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBs) follow-up. J Am Coll Cardiol. 1996;28:20\u20134.","journal-title":"J Am Coll Cardiol"},{"key":"7205_CR84","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/0735-1097(94)00345-Q","volume":"25","author":"T von Arnim","year":"1995","unstructured":"von Arnim T. Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. The TIBBS Investigators. J Am Coll Cardiol. 1995;25:231\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"7205_CR85","first-page":"794","volume":"17","author":"ZP Lin","year":"2013","unstructured":"Lin ZP, Dong M, Liu J. Bisoprolol improved endothelial function and myocardium survival of hypertension with stable angina: a randomized double-blinded trial. Eur Rev Med Pharmacol Sci. 2013;17:794\u2013801.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"7205_CR86","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1097\/00005344-199206000-00005","volume":"19","author":"ED de Muinck","year":"1992","unstructured":"de Muinck ED, Buchner-Moell D, van de Ven LL, Lie KI. Comparison of the safety and efficacy of bisoprolol versus atenolol in stable exercise-induced angina pectoris: a Multicenter International Randomized Study of Angina Pectoris (MIRSA). J Cardiovasc Pharmacol. 1992;19:870\u20135.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 5","key":"7205_CR87","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1097\/00005344-199006165-00008","volume":"16","author":"P Dorow","year":"1990","unstructured":"Dorow P, Thalhofer S, Bethge H, Disselhoff G, Wagner G. Long-term treatment of angina pectoris with bisoprolol or atenolol in patients with chronic obstructive bronchitis: a randomized, double-blind crossover study. J Cardiovasc Pharmacol. 1990;16(Suppl 5):S36-44.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7205_CR88","doi-asserted-by":"crossref","unstructured":"Maltz MB, Dymond DS, Nathan AW, Camm AJ. A comparison of once daily bisoprolol, 5 and 10 mg, and atenolol 100 mg in the treatment of angina pectoris. Eur Heart J. 1987;8 Suppl M:37\u201342.","DOI":"10.1093\/eurheartj\/8.suppl_M.37"},{"issue":"Suppl 11","key":"7205_CR89","first-page":"S148","volume":"8","author":"RS Kohli","year":"1986","unstructured":"Kohli RS, Lahiri A, Raftery EB. Management of chronic stable angina with once-daily bisoprolol or atenolol and long-term efficacy of bisoprolol. J Cardiovasc Pharmacol. 1986;8(Suppl 11):S148\u201353.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7205_CR90","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/oxfordjournals.eurheartj.a061771","volume":"6","author":"RS Kohli","year":"1985","unstructured":"Kohli RS, Khurmi NS, Kardash MM, Hughes LO, Lahiri A, Raftery EB. Efficacy of once daily bisoprolol in stable angina pectoris: an objective comparison with atenolol and long term follow-up. Eur Heart J. 1985;6:845\u201350.","journal-title":"Eur Heart J"},{"key":"7205_CR91","doi-asserted-by":"crossref","unstructured":"De Divitiis O, Liguori V, Di Somma S, et al. Bisoprolol in the treatment of angina pectoris: a double blind comparison with verapamil. Eur Heart J. 1987;8 Suppl M:43\u201354.","DOI":"10.1093\/eurheartj\/8.suppl_M.43"},{"key":"7205_CR92","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0167-5273(94)90208-9","volume":"43","author":"G Ruf","year":"1994","unstructured":"Ruf G, Trenk D, J\u00e4hnchen E, Roskamm H. Determination of the anti-ischemic activity of nebivolol in comparison with atenolol. Int J Cardiol. 1994;43:279\u201385.","journal-title":"Int J Cardiol"},{"key":"7205_CR93","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000446184","volume":"25","author":"M Ozaydin","year":"2016","unstructured":"Ozaydin M, Yucel H, Kocyigit S, et al. Nebivolol versus carvedilol or metoprolol in patients presenting with acute myocardial infarction complicated by left ventricular dysfunction. Med Princ Pract. 2016;25:316\u201322.","journal-title":"Med Princ Pract"},{"key":"7205_CR94","first-page":"45","volume":"14","author":"II Simova","year":"2009","unstructured":"Simova II, Todorova-Konstantinova RR, Denchev SV. Effects of nebivolol versus bisoprolol on endothelial function in hypertensive patients. Exp Clin Cardiol. 2009;14:45\u20139.","journal-title":"Exp Clin Cardiol"},{"key":"7205_CR95","first-page":"e6453","volume":"11","author":"R Kumar","year":"2019","unstructured":"Kumar R, Mal K, Begum J, Shaukat F. Comparison of nebivolol and bisoprolol for cardiovascular mortality in hypertensive patients. Cureus. 2019;11:e6453.","journal-title":"Cureus"},{"key":"7205_CR96","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2165\/00129784-200808010-00005","volume":"8","author":"LM Van Bortel","year":"2008","unstructured":"Van Bortel LM, Fici F, Mascagni F. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis. Am J Cardiovasc Drugs. 2008;8:35\u201344.","journal-title":"Am J Cardiovasc Drugs"},{"key":"7205_CR97","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1097\/CM9.0000000000000802","volume":"133","author":"YD Chen","year":"2020","unstructured":"Chen YD, Yang XC, Pham VN, et al. Resting heart rate control and prognosis in coronary artery disease patients with hypertension previously treated with bisoprolol: a sub-group analysis of the BISO-CAD study. Chin Med J (Engl). 2020;133:1155\u201365.","journal-title":"Chin Med J (Engl)"},{"issue":"Suppl 5","key":"7205_CR98","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1097\/00005344-199000165-00032","volume":"16","author":"JM Bouvier","year":"1990","unstructured":"Bouvier JM, Rabot D, Herrero G. Effect of bisoprolol and acebutolol on resting blood pressure and on exercise blood pressure profile in hypertensive patients: a comparative, single-blind study. J Cardiovasc Pharmacol. 1990;16(Suppl 5):S179\u201383.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7205_CR99","doi-asserted-by":"publisher","first-page":"e72102","DOI":"10.1371\/journal.pone.0072102","volume":"8","author":"WJ Zhou","year":"2013","unstructured":"Zhou WJ, Wang RY, Li Y, et al. A randomized controlled study on the effects of bisoprolol and atenolol on sympathetic nervous activity and central aortic pressure in patients with essential hypertension. PLoS One. 2013;8:e72102.","journal-title":"PLoS One"},{"key":"7205_CR100","first-page":"565","volume":"88","author":"NM Wheeldon","year":"1995","unstructured":"Wheeldon NM, MacDonald TM, Prasad N, Maclean D, Peebles L, McDevitt DG. A double-blind comparison of bisoprolol and atenolol in patients with essential hypertension. QJM. 1995;88:565\u201370.","journal-title":"QJM"},{"key":"7205_CR101","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/00005344-199312000-00002","volume":"22","author":"M Leeman","year":"1993","unstructured":"Leeman M, van de Borne P, Collart F, et al. Bisoprolol and atenolol in essential hypertension: effects on systemic and renal hemodynamics and on ambulatory blood pressure. J Cardiovasc Pharmacol. 1993;22:785\u201391.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7205_CR102","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/0002-9149(93)90216-Y","volume":"72","author":"JM Neutel","year":"1993","unstructured":"Neutel JM, Smith DH, Ram CV, Lefkowitz MP, Kazempour MK, Weber MA. Comparison of bisoprolol with atenolol for systemic hypertension in four population groups (young, old, black and nonblack) using ambulatory blood pressure monitoring. Bisoprolol Investigators Group. Am J Cardiol. 1993;72:41\u20136.","journal-title":"Am J Cardiol"},{"key":"7205_CR103","doi-asserted-by":"crossref","unstructured":"Lithell H, Selinus I, Hosie J, Frithz G, Weiner L. Efficacy and safety of bisoprolol and atenolol in patients with mild to moderate hypertension: a double-blind, parallel group international multicentre study. Eur Heart J. 1987;8 Suppl M:55\u201364.","DOI":"10.1093\/eurheartj\/8.suppl_M.55-a"},{"key":"7205_CR104","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0002-9343(93)90181-N","volume":"94","author":"JM Neutel","year":"1993","unstructured":"Neutel JM, Smith DH, Ram CV, et al. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. Am J Med. 1993;94:181\u20137.","journal-title":"Am J Med"},{"key":"7205_CR105","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1365-2125.1988.tb03363.x","volume":"26","author":"R Lewis","year":"1988","unstructured":"Lewis R, Maclean D, Ioannides C, Johnston A, McDevitt DG. A comparison of bisoprolol and atenolol in the treatment of mild to moderate hypertension. Br J Clin Pharmacol. 1988;26:53\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl 11","key":"7205_CR106","first-page":"S122","volume":"8","author":"FR B\u00fchler","year":"1986","unstructured":"B\u00fchler FR, Berglund G, Anderson OK, et al. Double-blind comparison of the cardioselective beta-blockers bisoprolol and atenolol in hypertension: the Bisoprolol International Multicenter Study (BIMS). J Cardiovasc Pharmacol. 1986;8(Suppl 11):S122\u20137.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7205_CR107","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/BF00314797","volume":"38","author":"MS Dixon","year":"1990","unstructured":"Dixon MS, Thomas P, Sheridan DJ. A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension. Eur J Clin Pharmacol. 1990;38:21\u20134.","journal-title":"Eur J Clin Pharmacol"},{"key":"7205_CR108","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1093\/ajh\/hpu245","volume":"2","author":"K Eguchi","year":"2015","unstructured":"Eguchi K, Hoshide S, Kario K. Effects of celiprolol and bisoprolol on blood pressure, vascular stiffness, and baroreflex sensitivity. Am J Hypertens. 2015;2:858\u201367.","journal-title":"Am J Hypertens"},{"key":"7205_CR109","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/hr.2016.101","volume":"40","author":"T Yang","year":"2017","unstructured":"Yang T, Jiang Y, Hao Y, et al. Comparison of bisoprolol to a metoprolol CR\/ZOK tablet for control of heart rate and blood pressure in mild-to-moderate hypertensive patients: the CREATIVE study. Hypertens Res. 2017;40:79\u201386.","journal-title":"Hypertens Res"},{"key":"7205_CR110","doi-asserted-by":"crossref","unstructured":"Haasis R, Bethge H. Exercise blood pressure and heart rate reduction 24 and 3 hours after drug intake in hypertensive patients following 4 weeks of treatment with bisoprolol and metoprolol: a randomized multicentre double-blind study (BISOMET). Eur Heart J. 1987;8 Suppl M:103\u201313.","DOI":"10.1093\/eurheartj\/8.suppl_M.103"},{"key":"7205_CR111","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/BF01857642","volume":"4","author":"D Bracchetti","year":"1990","unstructured":"Bracchetti D, Gradnik R, Alberti A, et al. A double-blind comparison of bisoprolol and captopril for treatment of essential hypertension in the elderly. Cardiovasc Drugs Ther. 1990;4:261\u20134.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7205_CR112","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/00005344-199705000-00008","volume":"29","author":"B Va\u00efsse","year":"1997","unstructured":"Va\u00efsse B, Herpin D, Asmar R, et al. Assessment of antihypertensive effect by blood pressure monitoring: applications to bisoprolol and lisinopril in a double-blind study. J Cardiovasc Pharmacol. 1997;29:612\u20137.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7205_CR113","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/0149-2918(95)80092-1","volume":"17","author":"K Saku","year":"1995","unstructured":"Saku K, Liu K, Takeda Y, Jimi S, Arakawa K. Effects of lisinopril and bisoprolol on lipoprotein metabolism in patients with mild-to-moderate essential hypertension. Clin Ther. 1995;17:1136\u201346.","journal-title":"Clin Ther"},{"key":"7205_CR114","doi-asserted-by":"crossref","unstructured":"Gosse P, Roudaut R, Herrero G, Dallocchio M. Beta-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy. J Cardiovasc Pharmacol. 1990;16 (Suppl 5):S145\u201350.","DOI":"10.1097\/00005344-199012000-00026"},{"key":"7205_CR115","first-page":"450","volume":"41","author":"G Liu","year":"2002","unstructured":"Liu G, Li M, Shi X, et al. Efficacy of domestic bisoprolol, enalapril and nifedipine retard in mild to moderate hypertension: a randomized double-blind multicenter clinical trial in China. Zhonghua Nei Ke Za Zhi. 2002;41:450\u20132.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"7205_CR116","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2147\/VHRM.S44568","volume":"9","author":"GD Radchenko","year":"2013","unstructured":"Radchenko GD, Sirenko YM, Kushnir SM, Torbas OO, Dobrokhod AS. Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial. Vasc Health Risk Manag. 2013;9:535\u201349.","journal-title":"Vasc Health Risk Manag"},{"key":"7205_CR117","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/11315250-000000000-00000","volume":"29","author":"G Parrinello","year":"2009","unstructured":"Parrinello G, Paterna S, Torres D, et al. One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosed hypertensive patients: a randomized, double-blind study. Clin Drug Investig. 2009;29:591\u2013600.","journal-title":"Clin Drug Investig"},{"issue":"Suppl 5","key":"7205_CR118","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1097\/00005344-199006165-00017","volume":"16","author":"J Oliv\u00e1n Martinez","year":"1990","unstructured":"Oliv\u00e1n Martinez J, Garcia MJ, Rodriguez Botaro A, Pizarro JL, Carretero J, Garrido M. Bisoprolol and nifedipine SR in the treatment of hypertension in the elderly. J Cardiovasc Pharmacol. 1990;16(Suppl 5):S95\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"key":"7205_CR119","doi-asserted-by":"crossref","unstructured":"Amabile G, Serradimigni A. Comparison of bisoprolol with nifedipine for treatment of essential hypertension in the elderly: comparative double-blind trial. Eur Heart J. 1987;8 Suppl M:65\u20139.","DOI":"10.1093\/eurheartj\/8.suppl_M.65"},{"key":"7205_CR120","doi-asserted-by":"crossref","unstructured":"Bueno J, Amiguet JA, Carasusan J, Cebollada J, Carretero J. Bisoprolol vs. chlorthalidone: a randomized, double-blind, comparative study in arterial hypertension. J Cardiovasc Pharmacol. 1990;16 Suppl 5:S189\u201392.","DOI":"10.1097\/00005344-199012000-00035"},{"key":"7205_CR121","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059\u201368.","journal-title":"Lancet"},{"key":"7205_CR122","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/sj.jhh.1000571","volume":"12","author":"L Van Nueten","year":"1998","unstructured":"Van Nueten L, Taylor FR, Robertson JI. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial. J Hum Hypertens. 1998;12:135\u201340.","journal-title":"J Hum Hypertens"},{"key":"7205_CR123","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3109\/10641969309041625","volume":"15","author":"G Simon","year":"1993","unstructured":"Simon G, Johnson ML. Comparison of antihypertensive and beta 1-adrenoceptor antagonist effect of nebivolol and atenolol in essential hypertension. Clin Exp Hypertens. 1993;15:501\u20139.","journal-title":"Clin Exp Hypertens"},{"key":"7205_CR124","doi-asserted-by":"publisher","first-page":"437","DOI":"10.4103\/0253-7613.83117","volume":"43","author":"VA Badar","year":"2011","unstructured":"Badar VA, Hiware SK, Shrivastava MP, Thawani VR, Hardas MM. Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension. Indian J Pharmacol. 2011;43:437\u201340.","journal-title":"Indian J Pharmacol"},{"key":"7205_CR125","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/sj.jhh.1000533","volume":"11","author":"R Fogari","year":"1997","unstructured":"Fogari R, Zoppi A, Lazzari P, et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens. 1997;11:753\u20137.","journal-title":"J Hum Hypertens"},{"key":"7205_CR126","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1097\/00004872-200209000-00024","volume":"20","author":"E Arosio","year":"2002","unstructured":"Arosio E, De Marchi S, Prior M, Zannoni M, Lechi A. Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress. J Hypertens. 2002;20:1793\u20137.","journal-title":"J Hypertens"},{"key":"7205_CR127","first-page":"310","volume":"11","author":"O Erdo\u011fan","year":"2011","unstructured":"Erdo\u011fan O, Ertem B, Altun A, et al. Comparison of antihypertensive efficacy of carvedilol and nebivolol in mild-to-moderate primary hypertension: a randomized trial. Anadolu Kardiyol Derg. 2011;11:310\u20133.","journal-title":"Anadolu Kardiyol Derg"},{"key":"7205_CR128","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1007\/s12325-016-0427-1","volume":"33","author":"G Grassi","year":"2017","unstructured":"Grassi G, Seravalle G, Brambilla G, et al. Multicenter randomized double-blind comparison of nebivolol plus HCTZ and Irbesartan plus HCTZ in the treatment of isolated systolic hypertension in elderly patients: results of the NEHIS study. Adv Ther. 2017;33:2173\u201387.","journal-title":"Adv Ther"},{"key":"7205_CR129","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1185\/03007995.2010.497326","volume":"26","author":"J Heitmann","year":"2010","unstructured":"Heitmann J, Greulich T, Reinke C, et al. Comparison of the effects of nebivolol and valsartan on BP reduction and sleep apnoea activity in patients with essential hypertension and OSA. Curr Med Res Opin. 2010;26:1925\u201332.","journal-title":"Curr Med Res Opin"},{"key":"7205_CR130","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/08038020310000104","volume":"1","author":"EA Rosei","year":"2003","unstructured":"Rosei EA, Rizzoni D, Comini S, et al. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study. Blood Press Suppl. 2003;1:30\u20135.","journal-title":"Blood Press Suppl"},{"key":"7205_CR131","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/17843286.1999.11754204","volume":"54","author":"L Van Nueten","year":"1999","unstructured":"Van Nueten L, Rish\u00f8j Nielsen M, Vertommen C, et al. Nebivolol versus enalapril in essential hypertension: a long-term double-blind comparative trial. Acta Clin Belg. 1999;54:19\u201325.","journal-title":"Acta Clin Belg"},{"key":"7205_CR132","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/sj.jhh.1000550","volume":"11","author":"L Van Nueten","year":"1997","unstructured":"Van Nueten L, Schelling A, Vertommen C, Dupont AG, Robertson JI. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomised trial. J Hum Hypertens. 1997;11:813\u20139.","journal-title":"J Hum Hypertens"},{"key":"7205_CR133","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/080370502760050421","volume":"11","author":"A Mazza","year":"2002","unstructured":"Mazza A, Gil-Extremera B, Maldonato A, Toutouzas T, Pessina AC. Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood Press. 2002;11:182\u20138.","journal-title":"Blood Press"},{"key":"7205_CR134","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/j.1552-4604.1992.tb05778.x","volume":"32","author":"Y Lacourci\u00e8re","year":"1992","unstructured":"Lacourci\u00e8re Y, Poirier L, Lefebvre J, Provencher P, Arnott W. Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol. 1992;32:660\u20136.","journal-title":"J Clin Pharmacol"},{"key":"7205_CR135","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/00045391-199807000-00006","volume":"5","author":"L Van Nueten","year":"1998","unstructured":"Van Nueten L, Lacourci\u00e8re Y, Vyssoulis G, et al. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial. Am J Ther. 1998;5:237\u201343.","journal-title":"Am J Ther"},{"key":"7205_CR136","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/j.1524-6175.2007.07548.x","volume":"9","author":"E Saunders","year":"2007","unstructured":"Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich). 2007;9:866\u201375.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"7205_CR137","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1161\/hc3001.094207","volume":"104","author":"N Tzemos","year":"2001","unstructured":"Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001;104:511\u20134.","journal-title":"Circulation"},{"key":"7205_CR138","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41371-017-0019-9","volume":"32","author":"DA Duprez","year":"2017","unstructured":"Duprez DA, Florea N, Duval S, Koukol C, Cohn JN. Effect of nebivolol or atenolol vs. placebo on cardiovascular health in subjects with borderline blood pressure: the EVIDENCE study. J Hum Hypertens. 2017;32:20\u20135.","journal-title":"J Hum Hypertens"},{"key":"7205_CR139","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jash.2014.12.013","volume":"9","author":"SS Hayek","year":"2015","unstructured":"Hayek SS, Poole JC, Neuman R, et al. Differential effects of nebivolol and metoprolol on arterial stiffness, circulating progenitor cells, and oxidative stress. J Am Soc Hypertens. 2015;9:206\u201313.","journal-title":"J Am Soc Hypertens"},{"key":"7205_CR140","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1161\/HYPERTENSIONAHA.114.04116","volume":"64","author":"LE Okamoto","year":"2014","unstructured":"Okamoto LE, Gamboa A, Shibao CA, et al. Nebivolol, but not metoprolol, lowers blood pressure in nitric oxide-sensitive human hypertension. Hypertension. 2014;64:1241\u20137.","journal-title":"Hypertension"},{"key":"7205_CR141","first-page":"283","volume":"8","author":"Y Lacourci\u00e8re","year":"1994","unstructured":"Lacourci\u00e8re Y, Arnott W. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hypertens. 1994;8:283\u20138.","journal-title":"J Hum Hypertens"},{"key":"7205_CR142","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/ajh\/7.2.137","volume":"7","author":"Y Lacourci\u00e8re","year":"1994","unstructured":"Lacourci\u00e8re Y, Lefebvre J, Poirier L, Archambault F, Arnott W. Treatment of ambulatory hypertensives with nebivolol or hydrochlorothiazide alone and in combination. A randomized, double-blind, placebo-controlled, factorial-design trial. Am J Hypertens. 1994;7:137\u201345.","journal-title":"Am J Hypertens"},{"key":"7205_CR143","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.amjcard.2008.08.063","volume":"103","author":"V Papademetriou","year":"2009","unstructured":"Papademetriou V. Comparison of Nebivolol monotherapy versus Nebivolol in combination with other antihypertensive therapies for the treatment of hypertension. Am J Cardiol. 2009;103:273\u20138.","journal-title":"Am J Cardiol"},{"key":"7205_CR144","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/jhh.2009.33","volume":"24","author":"JM Neutel","year":"2010","unstructured":"Neutel JM, Smith DH, Gradman AH. Adding nebivolol to ongoing antihypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I-II hypertension. J Hum Hypertens. 2010;24:64\u201373.","journal-title":"J Hum Hypertens"},{"key":"7205_CR145","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1001\/archinte.1994.00420130048008","volume":"154","author":"WH Frishman","year":"1994","unstructured":"Frishman WH, Bryzinski BS, Coulson LR, et al. A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide. Arch Intern Med. 1994;154:1461\u20138.","journal-title":"Arch Intern Med"},{"key":"7205_CR146","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/j.1552-4604.1995.tb05009.x","volume":"35","author":"WH Frishman","year":"1995","unstructured":"Frishman WH, Burris JF, Mroczek WJ, et al. First-line therapy option with low-dose bisoprolol fumarate and low-dose hydrochlorothiazide in patients with stage I and stage II systemic hypertension. J Clin Pharmacol. 1995;35:182\u20138.","journal-title":"J Clin Pharmacol"},{"key":"7205_CR147","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129\u2013200.","journal-title":"Eur Heart J"},{"key":"7205_CR148","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC\/AHA\/HFSA Focused Update of the 2013 ACCF\/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137\u201361.","journal-title":"Circulation"},{"key":"7205_CR149","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407\u201377.","journal-title":"Eur Heart J"},{"issue":"37","key":"7205_CR150","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"14","author":"M Roffi","year":"2016","unstructured":"Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;14(37):267\u2013315.","journal-title":"Eur Heart J"},{"key":"7205_CR151","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39:119\u201377.","journal-title":"Eur Heart J"},{"key":"7205_CR152","first-page":"e362","volume":"127","author":"PT O'Gara","year":"2013","unstructured":"O\u2019Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e362-425.","journal-title":"Circulation"},{"key":"7205_CR153","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"7205_CR154","doi-asserted-by":"publisher","first-page":"b1665","DOI":"10.1136\/bmj.b1665","volume":"338","author":"MR Law","year":"2009","unstructured":"Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.","journal-title":"BMJ"},{"key":"7205_CR155","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.phrs.2018.10.031","volume":"139","author":"M Sabid\u00f3","year":"2019","unstructured":"Sabid\u00f3 M, Thilo H, Guido G. Long-term effectiveness of bisoprolol in patients with angina: a real-world evidence study. Pharmacol Res. 2019;139:106\u201312.","journal-title":"Pharmacol Res"},{"key":"7205_CR156","doi-asserted-by":"publisher","first-page":"249","DOI":"10.4070\/kcj.2018.0431","volume":"49","author":"JY Cho","year":"2019","unstructured":"Cho JY. Beta-blockers in heart failure with preserved ejection fraction: could their use be vindicated as an acceptable option in the future treatment guideline? Korean Circ J. 2019;49:249\u201351.","journal-title":"Korean Circ J"},{"key":"7205_CR157","doi-asserted-by":"publisher","first-page":"238","DOI":"10.4070\/kcj.2018.0259","volume":"49","author":"SH Kim","year":"2019","unstructured":"Kim SH, Yun SC, Park JJ, et al. Beta-blockers in patients with heart failure with preserved ejection fraction: results from the Korea Acute Heart Failure (KorAHF) registry. Korean Circ J. 2019;49:238\u201348.","journal-title":"Korean Circ J"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07205-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-021-07205-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07205-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T12:32:06Z","timestamp":1664368326000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-021-07205-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,9]]},"references-count":157,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["7205"],"URL":"https:\/\/doi.org\/10.1007\/s10557-021-07205-y","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,9]]},"assertion":[{"value":"20 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"All authors reviewed the manuscript and approved its submission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"WAlH reports receiving honorarium from Merck Serono Middle East FZ LTD, Novo Nordisk, Sanofi Aventis, Boehringer-ingelheim, Servier, outside the submitted work. AAIA and SM are employees of Merck Serono Middle East FZ-LLC, an affiliate of Merck KGaA, Germany.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}